ISOLAGEN INC Form 8-K March 14, 2005

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

March 14, 2005

Date of Report (date of Earliest Event Reported)

ISOLAGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

(State or Other Jurisdiction of Incorporation or Organization)

001-31564

(Commission File No.)

87-0458888

(I.R.S. Employer Identification No.)

102 Pickering Way, Exton, Pennsylvania 19341

(Address of principal executive offices and zip code)

(484) 875-3099

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

Item 7.01 Regulation FD Disclosure

Isolagen announces that it will host a conference call on March 15, 2005 beginning at 5:00 P.M. ET to discuss the Company's full year and fourth fiscal quarter 2004 results and provide a business update. See Exhibit 99.1, which is specifically incorporated by reference herein, for further information.

Item 9.01 Financial Statements and Exhibits

(a)	Not applicable.
(b)	Not applicable.
(c)	Exhibits.
	99.1 Press release dated March 14, 2005

[THE SIGNATURE PAGE FOLLOWS.]

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOLAGEN, INC.

Date: March 14, 2005

By: /s/ JEFFREY TOMZ

Jeffrey Tomz

Chief Financial Officer

QuickLinks

[THE SIGNATURE PAGE FOLLOWS.] SIGNATURE